Search Results: 100% Pass Quiz High Pass-Rate Juniper - JN0-281 - Data Center, Associate (JNCIA-DC) New Braindumps Ebook š Open ā½ www.pdfvce.com š¢Ŗ enter ā” JN0-281 ļøā¬ ļø and obtain a free download š®Valid Exam JN0-281 Book
Results showed evidence of clinical activity for cirtuvivint in advanced cancer patients Excerpt from the Press Release: SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (āBiospliceā), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced today the presentation of new clinical data for cirtuvivint (SM08502), its…
Read More
Drug Combinationās Unique Mechanism of Action Enables Reactivation of Brain Adrenergic Function, Showing Improvements in Multiple Areas of Cognition Excerpt from the Press Release: SAN CARLOS, Calif. & LISBON, Portugal–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a data with…
Read More
ā Positive Phase 2 EXACT Trial results at 6-months underscore significant potential of investigational therapy in refractory angina ā Six-month data have since been sustained out to 12-months supporting durability of XC001 safety and efficacy profile ā XC001 targets unmet medical need among patients with refractory angina who have a debilitating quality-of-life burden and no…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced the completion of the Phase 1 clinical trial of VRG50635 in healthy adult volunteers. VRG50635 was dosed up to the maximum single and repeated doses planned, demonstrating a favorable…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) — InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society…
Read More
Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced results from an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting on longer follow-up data from the IMerge Phase 2 clinical trial of imetelstat, the Companyās first-in-class telomerase inhibitor, in lower risk…
Read More
Excerpt from the Press Release: Phase 2a Tolerability and Efficacy Data Supports Further Clinical Development of Samuraciclib in Combination with Fulvestrant in HR+, HER2- Breast Cancer Previously Treated with a CDK4/6 Inhibitor DUBLIN, Ireland and BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today…
Read More
ā Company anticipates reporting initial SER-155 safety and pharmacological data from study Cohort 1 in the coming months ā Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that enrollment in Cohort 2 in its SER-155 Phase 1b study is underway. SER-155, an investigational oral…
Read More
Excerpt from the article: “Genomics health technology startup Color is doing its part to address the global COVID-19 pandemic, and has detailed the steps itās taking to support expansion of testing efforts in a new blog post and letter from CEO Othman Laraki on Tuesday. The efforts include development of a high-throughput lab that can…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Immunicom, Inc., a clinical stage biotech, shared preliminary data from its metastatic triple-negative breast cancer (mTNBC) clinical trial with its novel breakthrough ImmunopheresisĀ®Ā therapy at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021. Immunicomās subtractive immunotherapies are designed to remove immune inhibitors and enhance patients natural immune…
Read More